XTL Biopharmaceuticals Company Description

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel.

Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome.

The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.

The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995.

XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

XTL Biopharmaceuticals Ltd.

Country	Israel
Founded	1993
Industry	Biological Products, Except Diagnostic Substances
Employees	10
CEO	Noam Band

Contact Details

Address: 26 Ben-Gurion St. Ramat Gan, 5112001 Israel
Phone	972 3 611 6600
Website	xtlbio.com

Stock Details

Ticker Symbol	H2K2
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Noam Band	Chief Executive Officer
Itay Weinstein	Chief Financial Officer